CTL1 Inhibition for Macrophage-Mediated Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments fail to effectively prevent or ameliorate macrophage-mediated inflammatory and degenerative diseases by targeting choline uptake and phosphorylation pathways that contribute to IL-1β production.
Innovation Solution
Inhibition of choline-transporter-like protein 1 (CTL1) activity or expression, and/or choline phosphorylation by choline kinases (ChoKα and ChoKβ), using inhibitors such as small molecules, peptides, antisense oligonucleotides, antibodies, or nucleic acids like siRNA, to reduce IL-1β and IL-18 production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If choline uptake and phosphorylation are enhanced to support membrane phospholipid synthesis and cellular metabolism, then cellular function and proliferation are improved, but IL-1β production and macrophage-mediated inflammation are exacerbated
Solution Approach 1:
The invention extracts and inhibits the specific step of choline phosphorylation by ChoKα, separating this metabolic step from the overall choline utilization pathway. By selectively blocking ChoKα activity with inhibitors (e.g., MK-5172, RSM932A) or antisense oligonucleotides, the patent reduces IL-1β production while allowing other choline metabolic pathways to continue supporting cellular function.
Solution Approach 2:
The invention applies local quality by targeting a specific enzyme (ChoKα) within the choline metabolic pathway rather than blocking all choline utilization. This selective inhibition at the ChoKα step allows differential outcomes: reduced phosphocholine and IL-1β production in inflammatory contexts, while preserving choline uptake and alternative metabolic routes for membrane synthesis and cellular metabolism.
2Reliability
If NLRP3 inflammasome activation is triggered to respond to pathogens and tissue damage, then immune defense is enhanced, but chronic inflammation and tissue damage are caused
Solution Approach 1:
The invention performs preliminary action by inhibiting ChoKα activity before NLRP3 inflammasome activation can lead to excessive IL-1β production. By pre-blocking the choline phosphorylation step that supplies phosphocholine for inflammatory mediator synthesis, the patent attenuates the harmful effects of NLRP3 activation while preserving the initial immune response capability.
Solution Approach 2:
The invention converts the harmful effect of enhanced choline phosphorylation (which drives IL-1β production and chronic inflammation) into a beneficial outcome by selectively inhibiting ChoKα. This conversion reduces inflammatory pathology in diseases like gout, rheumatoid arthritis, and atherosclerosis, while the inhibited pathway's resources can be redirected to support non-inflammatory cellular functions.
3Quantity of substance
If choline kinase activity is increased to support phosphatidylcholine synthesis, then membrane phospholipid production is improved, but IL-1β and IL-18 secretion are enhanced
Solution Approach 1:
The invention extracts and selectively inhibits the ChoKα-catalyzed phosphorylation step from the choline metabolic pathway. This separation allows the patent to specifically reduce phosphocholine and IL-1β production while potentially preserving other aspects of phospholipid metabolism through alternative pathways or compensated synthesis mechanisms.
Solution Approach 2:
The invention applies parameter changes by modulating ChoKα activity levels through inhibition (using small molecule inhibitors, antisense oligonucleotides, or RNAi). By changing the kinetic parameter of ChoKα activity, the patent shifts the metabolic flux away from IL-1β-promoting pathways while attempting to maintain essential phospholipid synthesis through compensatory mechanisms.
Data Source
AI summary
Provided herein are methods of treating macrophage-mediated inflammatory diseases and disorders. Also, disclosed are methods for screening for agents useful in such methods.